The study investigated the efficacy and safety of pegcetacoplan in patients with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). 124 patients aged 12 and over participated in the study. Patients treated with pegcetacoplan achieved an average decrease in urinary protein of 68% compared to placebo after 26 weeks. In 67% of the children, a complete remission of the disease was achieved, and in 72% a complete finding was confirmed on the kidney biopsy. The results were consistent in both adolescents and adults, in patients with both autologous and transplanted kidneys. The drug has been approved as first-line treatment for these conditions in patients 12 years of age and older. The study confirmed the favorable safety profile of the drug.